CION Ameerpet
With ovarian cancer, where the first operation happens changes what the rest of the treatment can achieve. That decision is usually made in a week, under pressure, by a family with no way to compare one hospital against another. This page gives you the criteria specialists actually use, and the questions that reveal them.
Families search for the best ovarian cancer hospital and get back a list of buildings — bed counts, machines, accreditation logos, a photograph of a lobby. Almost none of that predicts how a woman with ovarian cancer will do. What predicts it is narrower, and slightly uncomfortable: who stands at the operating table, how much disease that person can safely remove, and whether the decision about the order of treatment was made by a team or by one doctor in a five-minute consultation.
Ovarian cancer is unusual in this respect. For many cancers, treatment is standardised enough that the centre matters less than the protocol. Here the operation itself is the variable. Advanced ovarian cancer spreads as deposits across the peritoneum, the omentum, the diaphragm and the bowel surface, and removing all of it is a long, demanding operation that some teams do routinely and others attempt occasionally. The difference is recorded in the operation note as residual disease — and residual disease is the strongest surgical predictor of how long a woman lives.
So the useful version of how to choose an ovarian cancer hospital is not a ranking. It is a short list of things you can verify by asking, and a smaller list of answers that should make you pause. That is the rest of this page. For the local landscape specifically, our guide to choosing an ovarian cancer hospital in Hyderabad works through the options city by city.
Chemotherapy protocols are broadly standard across good centres. Surgical completeness is not. That is where centres genuinely differ, and it is the hardest thing for a family to see from the outside.
Surgery first, or chemotherapy first with an operation in the middle? Getting that call right needs imaging, sometimes a laparoscopic assessment, and a tumour board — not a single opinion.
The centre that operates does not have to be the centre that gives chemotherapy for the next five months. Choosing well for surgery does not mean travelling for a year.
Two findings about ovarian cancer surgery are consistent across international guidance. First, who operates matters: NCCN and the ESMO–ESGO consensus both state that surgery for suspected ovarian cancer should be performed by a gynaecologic oncologist. Second, how completely the disease is removed matters more than almost anything else done in theatre — leaving no visible residual disease (R0) is the strongest surgical predictor of survival in advanced disease. ESGO’s published quality indicators for advanced ovarian cancer surgery go further and set a minimum annual caseload for a centre, on the evidence that higher-volume units achieve complete resection more often and manage its complications better. Source: ESGO Quality Indicators for Advanced Ovarian Cancer Surgery (Querleu et al., 2016); NCCN Ovarian Cancer guidelines; ESMO–ESGO Consensus Conference on ovarian cancer (2019).
These are the things gynaecologic oncologists themselves look at when they refer a patient elsewhere. Each can be established by asking a direct question, and none of them requires you to understand oncology.
This is the criterion with the most evidence behind it. Ovarian cancer surgery is not general gynaecology and it is not general surgery. It needs a surgeon trained specifically in gynaecologic oncology, comfortable operating on the upper abdomen, the diaphragm and the bowel in the same sitting, and able to judge during the operation how much disease can be removed safely.
Ask by name: who will perform the operation, and what is their gynaecologic-oncology training? A centre that answers immediately and specifically is telling you something. A centre that answers with a department name rather than a person is telling you something too.
Complete resection — no visible tumour left at the end of the operation, recorded as R0 — is the surgical goal in advanced ovarian cancer, and centres that measure it tend to achieve it more often. The figure itself varies with case mix, so a lower number is not automatically damning. What matters is whether the team knows their figure at all.
A unit that audits its own residual-disease rate treats it as a target rather than an afterthought. Our guide to optimal cytoreduction and why residual disease matters explains what R0, R1 and suboptimal debulking mean on an operation note, so you can read your own.
Volume is a proxy for rehearsed judgement, a theatre team that has done this before, and anaesthetic and critical-care services that know what a long cytoreduction demands. ESGO’s quality indicators for advanced ovarian cancer surgery set a minimum annual caseload for a centre — at least twenty cytoreductive procedures a year — precisely because complete resection rates rise with experience.
In practice you are asking one question: is advanced ovarian cancer surgery something this team does most weeks, or something they do a few times a year? Volume is the most commonly ignored of the debulking centre criteria, because it is the one nobody advertises.
The most consequential decision in advanced ovarian cancer is not which drug but which order: primary surgery followed by chemotherapy, or chemotherapy first with an interval operation. That judgement rests on imaging, fitness, disease distribution and sometimes a diagnostic laparoscopy, and a group makes it better than an individual.
Ask whether your case will be discussed by a multidisciplinary board with medical oncology, surgery, radiology and pathology present, and whether that happens before the plan is fixed. A board that convenes only to review completed cases is a governance exercise, not a decision-making one.
Ovarian tumours are diagnostically difficult. Borderline tumours, low-grade versus high-grade serous cancers, clear cell and mucinous subtypes and germ-cell tumours behave differently and are treated differently, and separating them reliably needs a pathologist who reports gynaecological specimens regularly.
Frozen section — a rapid microscopic assessment while you are still under anaesthetic — matters when the diagnosis is uncertain. It can change the extent of the operation, and it can protect fertility in a young woman whose tumour turns out to be benign or borderline. Ask whether it is available on the day, not in principle.
Cytoreductive surgery for advanced ovarian cancer can run for many hours and may involve bowel resection, splenectomy or stripping of the diaphragm. That requires anaesthetists used to long abdominal cases, a dependable blood bank, high-dependency or intensive-care beds free on the day, and colorectal support if the bowel is involved.
This is the least glamorous criterion and one of the most important. A team can be entirely capable of the surgery and still be limited by what stands behind them. Asking where you will recover, and who is available overnight, is a fair question and a revealing one.
Surgery is a fortnight of your life. Chemotherapy, maintenance therapy and follow-up are the next several years of it. A centre that operates beautifully and then hands you back with a discharge summary and no onward plan has solved half the problem.
Ask who will supervise chemotherapy, whether maintenance therapy will be considered and on what basis, and whether treatment can be delivered close to where you live. Expertise matters more than distance for the operation; distance matters more than prestige for the twenty visits that follow it.
Every woman diagnosed with epithelial ovarian cancer should be offered genetic testing, whatever her family history. BRCA and HRD status guides which maintenance therapy is appropriate, and a pathogenic variant has direct consequences for sisters, daughters and mothers, who can then be tested and offered risk-reducing options of their own.
A centre that raises genetic counselling in the first weeks is working to guideline. One that raises it a year later, or not at all, has missed something that affects both your treatment and your family. Ask when testing will be arranged and who will explain the result.
You are allowed to ask all of these, and a good team will not mind. The answers tell you more than any brochure — and so does the tone in which they are given.
| Ask this | Why it matters | What a straight answer sounds like |
|---|---|---|
| Who exactly will operate, and what is their gynaecologic-oncology training? | The criterion with the most evidence behind it. | A named surgeon, their training, and an offer to meet them before you decide. |
| How many advanced debulking operations does this unit do in a year? | Volume tracks complete-resection rates and complication management. | A number, given without hesitation, and a sense of whether this is weekly or occasional work. |
| Do you record residual disease after surgery, and what is your R0 rate? | A team that measures completeness is aiming for it. | “We record it, here is roughly where we sit, and here is why your case may differ.” |
| Will my case be discussed at a tumour board before the plan is fixed? | Surgery first or chemotherapy first is the highest-stakes call. | A named meeting, a day of the week, and who sits on it. |
| Is frozen section available during the operation? | It can change the extent of surgery and protect fertility. | “Yes, on the day, reported by our gynaecological pathologist.” |
| Who gives the chemotherapy afterwards, and can it be given near my home? | The years after surgery are where continuity is won or lost. | A named medical oncologist, and a realistic answer about travel. |
| Will I be offered BRCA and HRD testing, and when? | It guides maintenance therapy and protects your relatives. | “At diagnosis, with counselling, and the result comes back to this clinic.” |
| Can I have a written estimate, and what is not included in it? | Ovarian cancer bills are long and staged; surprises are avoidable. | An itemised estimate, plus what changes if the operation is longer than planned. |
*Take this list to every centre you are considering, including this one. Comparing three sets of answers is far more useful than comparing three reputations.
None of these means a centre is bad, and none is a reason to panic. Each is a reason to ask one more question, or to have your file reviewed elsewhere before the date is fixed.
If the answer to who is operating is a department rather than a person, keep asking until you have a name.
If the conversation about surgery is entirely about the incision, the days in hospital and the bill, and never about how much disease can be removed, then the goal of the operation has not been set.
A date offered before cross-sectional imaging has been reviewed, and before the sequence has been discussed by a team, is a scheduling decision rather than a clinical one.
Confident teams are relaxed about it. Discomfort at the question is worth noticing, because a second opinion in ovarian cancer is standard practice, not disloyalty.
Nobody can promise a specific outcome from ovarian cancer surgery. A team that guarantees results is describing its marketing rather than its medicine.
Treatment is billed in stages over months. A centre that will not put an itemised estimate in writing, including what could push the figure higher, is asking you to sign blind.
If two or more of these apply, have your reports reviewed elsewhere before the operation is scheduled. The window to change your mind closes once surgery begins, and the first operation is the one that matters most.
Bring your scans, blood tests and any biopsy report. A 45-minute consultation will tell you which stage of the decision you are actually at, whether surgery or chemotherapy should come first, and what to ask the centre you are considering. It is free, and there is no obligation to be treated here.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
A second opinion costs you nothing at CION and takes one appointment. If the plan you already have is the right one, we will tell you so plainly.
Most families have days rather than weeks, and are choosing while still absorbing a diagnosis. This is the order that wastes the least time and still gets the decision right.
Gather the actual documents: ultrasound and CT images on a disc or drive, the radiology reports, CA-125 and other blood results, any biopsy or cytology report, and a list of your other conditions and medicines. Reports read off a phone photograph waste an appointment. A complete file lets any specialist give you a real opinion the first time.
Not five. One independent review by a team that treats ovarian cancer routinely will confirm the diagnosis, the stage as far as imaging can show it, and — most importantly — whether surgery or chemotherapy should come first. Ask for it in writing: a written second opinion is what makes two plans comparable when you sit down to choose.
Apply the eight criteria above and weight the first three hardest: a gynaecologic oncologist, a unit that measures residual disease, and a unit that operates on this disease often. Travel is worth it for this step in a way it is not worth it for anything else in ovarian cancer care.
This is a different question, and treating it as the same question is the commonest mistake families make. Chemotherapy runs over months and follows standard protocols. Choose for continuity, for a named oncologist who knows your case, and for a centre you can reach on a day when you feel unwell.
Ask for an itemised written estimate, confirm what your insurance or Aarogyasri covers and what it does not, and ask specifically what happens to the figure if the operation runs long or a bowel resection is needed. Cost surprises in ovarian cancer usually arrive at the second or third stage, not the first.
Once the plan and the place are settled, delay stops being cautious. Ovarian cancer rarely changes dramatically in a fortnight, but the decision window is not open-ended either. Set the date, and put your energy into the treatment rather than the choosing.
If you are at the very beginning and none of this is clear yet, start with the complete ovarian cancer guide and come back to this page once the stage is known.
Every family tries to compare centres by outcome figures, and every family hits the same wall. Published survival numbers for ovarian cancer are averaged across stages, subtypes and ages, drawn from women treated years ago under older protocols, and they mix centres that operate to complete resection with centres that do not. Two hospitals quoting different figures may simply be treating different patients.
There is also a selection effect nobody advertises. A unit that declines the hardest cases — extensive upper-abdominal disease, frail patients, recurrence — will publish better numbers than a unit that accepts them. The centre with the better statistic can be the centre doing the easier work. That is why guidance concentrates on process measures, such as whether a gynaecologic oncologist operates and whether complete resection is achieved, rather than on comparing raw survival between hospitals.
CION publishes its own one-year survival alongside the national figure so the comparison is visible rather than implied. For ovarian cancer, 81.0% of CION patients are alive at one year, against a national figure of 73.7%. That is a one-year figure across a whole treated population — not a cure rate, and not a prediction for any individual. Your own outlook depends on stage, subtype, how completely disease can be removed and your general health, and it is a conversation for your oncologist rather than a number to shop with.
CION ovarian cancer patients alive at one year from diagnosis. *One-year survival, CION treated population.
The comparable national figure for ovarian cancer. *One-year survival; national registry data.
Who operates, how often they operate, whether residual disease is measured, and whether a tumour board sets the sequence. Those are checkable. Rankings are not.
*One-year survival rates. CION figures reflect CION’s treated patient population; national figures are drawn from published Indian cancer registry data. Survival statistics describe groups, not individuals — discuss your own prognosis with your treating oncologist.
It would be easy to end a page like this by claiming CION meets all eight criteria under one roof. The honest answer is more useful to you. CION is a medical oncology network, and we are plain about the line between what we deliver ourselves and what we arrange with others.
Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there. What we do is the work of getting you to the right surgical team, with your imaging reviewed and your case discussed at a tumour board first — and we say so upfront rather than letting you discover it at admission. HIPEC, intraperitoneal chemotherapy and PET-CT are arranged the same way.
What happens in-house is everything that follows and everything that runs alongside: chemotherapy and maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, genetic counselling with BRCA and HRD testing, nutrition support, and structured survivorship follow-up. That is the part of ovarian cancer care measured in years rather than days, and it is the part where being near home stops being a convenience and becomes the reason treatment gets finished on time.
Your first consultation is free and runs to about 45 minutes — long enough to read your file properly, tell you which stage of this decision you are actually at, and give you the questions to take to whichever centre you are considering. There is no obligation to be treated here. If the plan you already have is the right one, we will say so.
Free, unhurried, with a specialist. Bring your scans and reports; leave with a view of the plan and the questions to ask.
Medical oncology, surgery, radiology and pathology review the case together, and the surgery-first versus chemotherapy-first call is made there.
Debulking is performed by specialist gynaecologic-oncology surgeons at partner centres and may be billed there. We would rather be plain about that than have you find out later.
Chemotherapy, maintenance therapy and follow-up delivered close to where you live, across Telangana and Andhra Pradesh.
Decisions for healing, not billing. If a test or a treatment will not change what we do next, we will tell you that rather than order it.
Three things carry most of the weight, and none of them is visible in a brochure. First, a gynaecologic oncologist performs the surgery rather than a general gynaecologist or general surgeon. Second, the unit does enough advanced ovarian cancer operations to be practised at them, and measures how often it achieves complete resection with no visible disease left behind. Third, the decision about whether surgery or chemotherapy comes first is made by a multidisciplinary tumour board before the plan is fixed, rather than by one doctor in a short consultation. After that, look for gynaecological pathology with frozen section available on the day, intensive-care and blood-bank support for a long operation, genetic testing offered at diagnosis, and a clear plan for who delivers chemotherapy afterwards and where.
Yes, and this is the part of the decision with the most evidence behind it. Advanced ovarian cancer spreads as deposits across the peritoneum, omentum, diaphragm and bowel surface, and removing all of it is a long operation requiring specific training. NCCN and the ESMO-ESGO consensus both recommend that surgery for suspected ovarian cancer be performed by a gynaecologic oncologist. The measurable difference is residual disease: how much visible tumour remains when the operation ends. Complete resection is the strongest surgical predictor of survival in advanced disease, and teams who do this work regularly achieve it more often. Asking who will operate, and what their gynaecologic-oncology training is, is an ordinary and reasonable question.
European quality-indicator work from ESGO sets a minimum annual caseload for centres performing surgery for advanced ovarian cancer, at least twenty cytoreductive procedures a year, on the evidence that higher-volume units achieve complete resection more often and manage complications better. Treat that as a floor rather than a target, and treat the manner of the answer as informative too. In practice you are establishing one thing: whether this is work the team does most weeks, or work they do a few times a year. A centre that knows its figure and offers it without hesitation is a centre that pays attention to it. A centre that cannot answer has already answered.
Not necessarily, and assuming they must is the commonest mistake families make. These are two questions with two different answers. For surgery, choose the most experienced gynaecologic-oncology team you can reach, even if it means travelling, because the completeness of that one operation shapes everything after it. For chemotherapy, which runs over months and follows standard protocols, choose continuity and proximity: a named oncologist who knows your case, at a centre you can reach on a day when you feel unwell. What matters is that the two teams communicate, that the operation note and histopathology reach the medical oncologist, and that one person owns the overall plan. Splitting care deliberately is reasonable. Splitting it by accident is not.
Size is not the variable. A large general hospital brings intensive care, a blood bank and other specialties under one roof, which genuinely matters during a long cytoreductive operation. A cancer-focused network brings routine exposure to the disease, a tumour board that meets for oncology rather than for everything, and continuity through the years of treatment that follow surgery. The failure mode of a general hospital is a surgeon who operates on ovarian cancer occasionally. The failure mode of a small specialist unit is thin support when an operation becomes complicated. Ask the specific questions instead of judging by category: who operates, how often, what happens if the case is difficult, and who supervises treatment afterwards.
Ask for things that exist in writing. A named surgeon with stated gynaecologic-oncology training. An itemised written estimate that says what is not included. A named tumour board with a day it meets. A second opinion from another centre, in writing, so you have two plans that can be compared side by side rather than two impressions. You can also ask to meet the operating surgeon before the date is fixed, which is a reasonable request that good teams accommodate. If any of this produces evasion rather than an answer, that is itself the information you were looking for. You are not being difficult; you are making a decision that cannot be revisited afterwards.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house: chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, along with genetic counselling, BRCA and HRD testing, nutrition support and survivorship follow-up. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there, and HIPEC, intraperitoneal chemotherapy and PET-CT are arranged the same way. We say that upfront rather than leaving it to be discovered at admission. Every case that raises a question is reviewed at a tumour board, and if the plan you already have elsewhere is the right one, we will tell you plainly.